AstraZeneca and Halix have signed an agreement where the Netherlands-based biopharma will manufacture the Covid-19 vaccine in development by the British drugmaker and the University of Oxford says Halix.
Halix will be responsible for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based Covid-19 vaccine. Under the agreement, it will provide commercial manufacturing of drug substance at its cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, Halix plans to expand with two additional viral vector production lines.
The vaccine was co-invented by the University of Oxford and its spin-out company Vaccitech.
"Building on the solid foundations made with the University of Oxford, it’s our pleasure to expand our manufacturing support of AZD1222 with AstraZeneca," said Alex Huybens, chief operations officer of Halix. "Through the consortium, the partners are bringing their collective expertise and manufacturing capabilities to support vaccine production and combat this evolving crisis."
Read the Halix statement.